Dr. Marc Rothenberg is a preeminent physician-scientist and internationally recognized authority in pediatric allergy and immunology research. He currently serves as Director of the Division of Allergy and Immunology, Bunning Professor of Pediatrics, and Director of the Cincinnati Center for Eosinophilic Disorders at Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine. After earning his MD, PhD from Harvard Medical School in 1990, he completed pediatric residency and dual fellowships in Immunology/Allergy and Hematology/Oncology at Boston Children's Hospital. Since joining Cincinnati Children's in 1996, he has established one of the world's leading research programs dedicated to understanding and treating eosinophilic disorders, transforming the institution into a global epicenter for this specialized field of immunology.
Dr. Rothenberg's pioneering research has fundamentally elucidated the molecular mechanisms underlying eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis. His laboratory identified critical pathways regulating allergic inflammation and eosinophil function, providing the scientific foundation for targeted therapeutic interventions that have directly translated to clinical practice. These discoveries catalyzed the development of a new class of anti-eosinophil therapeutics and ultimately led to the first FDA-approved drug for eosinophilic esophagitis, revolutionizing treatment paradigms for thousands of patients worldwide. His work demonstrating the role of specific cytokines and signaling pathways in eosinophilic disorders has established new diagnostic criteria and treatment algorithms that are now standard practice across the field.
Beyond his laboratory breakthroughs, Dr. Rothenberg has profoundly shaped the global landscape of eosinophil research through his leadership of the Consortium of Eosinophilic Disease Researchers within the NIH Rare Disease Clinical Research Network and his presidency of the International Eosinophil Society. He has established the innovative CURED Laboratory framework that integrates basic science with clinical translation, sharing findings globally through the EGIDExpress Data Sharing portal. Dr. Rothenberg has trained generations of scientists and clinicians who now lead independent programs worldwide, extending his scientific legacy across the field. His current research integrates cutting-edge genetic approaches, stem cell technology, and artificial intelligence to develop precision diagnostics and curative strategies for patients with eosinophilic disorders, maintaining his position at the forefront of translational immunology research.
